Loading
NASDAQHealthcareMedical - Specialties
Latest quote
$8.56
+$0.05 · +0.59%
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Latest quote
$8.56
+$0.05 · +0.59%
After-hours
$8.56
$0.00 · 0.00%
Oct 8, 4:04 PM ET
Regular session · ET · Market data may be delayed.
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Day range
Current $8.56
52-week range
Current $8.56
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
56
Mixed
Risk
54
Elevated Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Day range
Current $8.56
52-week range
Current $8.56
| Metric (USD) | FY2025 |
|---|---|
| Revenue | 32.04M USD |
| Cost of goods sold | 6.07M USD |
| Gross profit | 25.98M USD |
| Research and development | 6.52M USD |
| Selling, general, and administrative | 65.83M USD |
| Operating expenses | 72.34M USD |
| Interest expense | 967.37K USD |
| Depreciation and amortization | 151.66K USD |
| Operating income | −46.37M USD |
| Net income | −46.5M USD |
Company facts updated Oct 8, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$25.00
192.06% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI3.57M0.00%2.3T USD0.03%$379.55-0.39%
iShares Russell 2000 ETFIWM1.71M0.00%78.56B USD0.19%$277.63-0.03%
Vanguard Extended Market ETFVXF1.29M0.00%95.4B USD0.05%$233.16-0.14%
iShares Russell 2000 Growth ETFIWO455.06K0.00%14.25B USD0.24%$353.14-0.63%
Schwab U.S. Small-Cap ETFSCHA448.05K0.00%21.7B USD0.03%$32.645+0.11%
iShares Micro-Cap ETFIWC257.77K0.02%1.33B USD0.60%$182.68-0.37%
Vanguard Russell 2000 ETFVTWO132.61K0.00%18B USD0.06%$112.1-0.10%
Global X - Russell 2000 ETFRSSL40.67K—1.43B USD0.08%$108.6-0.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCVanguard Russell 2000 ETFVTWOGlobal X - Russell 2000 ETFRSSLAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
